Unit
Brustzentrum St.Gallen
BZ · Dept. IV
Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?
Knauer M, Filipits M, Dubsky P. Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?. Breast Care (Basel) 2014; 9:97-100.
May 1, 2014Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?
May 1, 2014Breast Care (Basel) 2014; 9:97-100
Knauer Michael, Filipits Martin, Dubsky Peter
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
von Minckwitz G, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching P, Sinn B, Engels K, Mehta K, Nekljudova V, Klare P, Eidtmann H, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer J, Jackisch C, Paepke S, Gerber B, Zahm D, Kümmel S, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15:747-56.
Apr 30, 2014Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Apr 30, 2014Lancet Oncol 2014; 15:747-56
von Minckwitz Gunter, Huober Jens, Costa Serban, Tesch Hans, Hanusch Claus, Hilfrich Jörn, Khandan Fariba, Fasching Peter A, Sinn Bruno V, Engels Knut, Mehta Keyur, Nekljudova Valentina, Klare Peter, Eidtmann Holger, Schneeweiss Andreas, Loibl Sibylle, Salat Christoph, Denkert Carsten, Rezai Mahdi, Blohmer Jens U, Jackisch Christian, Paepke Stefan, Gerber Bernd, Zahm Dirk M, Kümmel Sherko, Untch Michael
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)
Gerber B, Loibl S, Nekljudova V, Hauschild M, Huober J, Blohmer J, Kunz G, Jackisch C, Solbach C, Hanusch C, Kittel K, Schrader I, Eggemann H, Tesch H, Fasching P, Rezai M, Eidtmann H, von Minckwitz G, Untch M. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). Ann Surg Oncol 2014; 21:2517-24.
Apr 18, 2014Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)
Apr 18, 2014Ann Surg Oncol 2014; 21:2517-24
Gerber Bernd, Loibl Sibylle, Nekljudova Valentina, Hauschild Maik, Huober Jens, Blohmer Jens-Uwe, Kunz Georg, Jackisch Christian, Solbach Christine, Hanusch Claus, Kittel Kornelia, Schrader Iris, Eggemann Holm, Tesch Hans, Fasching Peter, Rezai Mahdi, Eidtmann Holger, von Minckwitz Gunter, Untch Michael
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
Templeton A, Ruhstaller T, Thürlimann B, Zaman K, von Moos R, Rochlitz C, Winterhalder R, von Rohr L, Müller A, Winkler A, Borner M, Dietrich D, Beyeler M, Hsu Schmitz S, Sun H, Surber C, Ribi K, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 2014; 23:244-9.
Mar 20, 2014Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
Mar 20, 2014Breast 2014; 23:244-9
Templeton Arnoud, Ruhstaller Thomas, Thürlimann Beat, Zaman Khalil, von Moos Roger, Rochlitz Christoph, Winterhalder Ralph C, von Rohr Lukas, Müller Andreas, Winkler Annette, Borner Markus, Dietrich Daniel, Beyeler Michael, Hsu Schmitz Shu-Fang, Sun Hong, Surber Christian, Ribi Karin, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
Jörger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, Cerny T. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol 2014; 70:719-25.
Mar 11, 2014Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
Mar 11, 2014Eur J Clin Pharmacol 2014; 70:719-25
Jörger Markus, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem Stefan, Thürlimann Beat, Cerny Thomas
Response
Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Response. J Natl Cancer Inst 2014; 106:djt452.
Feb 28, 2014Response
Feb 28, 2014J Natl Cancer Inst 2014; 106:djt452
Moebus Volker, Untch Michael, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, Nitz Ulrike A, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Huober Jens, Schneeweiss Andreas, Jackisch Christian, AGO Breast Study Group
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer
Filipits M, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens J, Gnant M, Dubsky P, Mlineritsch B, Singer C, Nielsen T, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Austrian Breast and Colorectal Cancer Study Group. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 2014; 20:1298-305.
Feb 11, 2014The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer
Feb 11, 2014Clin Cancer Res 2014; 20:1298-305
Filipits Martin, Bauernhofer Thomas, Hubalek Michael, Knauer Michael, Trapl Harald, Fesl Christian, Schaper Carl, Ferree Sean, Liu Shuzhen, Cowens J Wayne, Gnant Michael, Dubsky Peter, Mlineritsch Brigitte, Singer Christian F, Nielsen Torsten O, Rudas Margaretha, Greil Richard, Stöger Herbert, Jakesz Raimund, Bago-Horvath Zsuzsanna, Dietze Otto, Regitnig Peter, Gruber-Rossipal Christine, Müller-Holzner Elisabeth, Austrian Breast and Colorectal Cancer Study Group
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
Loibl S, Denkert C, Hilfrich J, Konecny G, Fett W, Stickeler E, Harbeck N, Mehta K, Nekljudova V, von Minckwitz G, Huober J, Kümmel S, Volz C, Mau C, Blohmer J, Costa S, Eidtmann H, Fasching P, Gerber B, Hanusch C, Jackisch C, Untch M. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat 2014; 144:153-62.
Feb 7, 2014Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
Feb 7, 2014Breast Cancer Res Treat 2014; 144:153-62
Loibl Sibylle, Denkert Carsten, Hilfrich Jörn, Konecny Gottfried E, Fett Werner, Stickeler Elmar, Harbeck Nadia, Mehta Keyur M, Nekljudova Valentina, von Minckwitz Gunter, Huober Jens, Kümmel Sherko, Volz Cristina, Mau Christine, Blohmer Jens-Uwe, Costa Serban D, Eidtmann Holger, Fasching Peter A, Gerber Bernd, Hanusch Claus, Jackisch Christian, Untch Michael
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Decensi A, Coates A, Goldhirsch A, Gelber R, Price K, Johansson H, Zaman K, Schönenberger A, Debled M, Campone M, Monnier A, Tondini C, McIntosh C, Thürlimann B, Guerrieri-Gonzaga A, Sun Z, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat 2014; 144:321-9.
Feb 1, 2014Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Feb 1, 2014Breast Cancer Res Treat 2014; 144:321-9
Decensi Andrea, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Price Karen N, Johansson Harriet, Zaman Khalil, Schönenberger Astrid, Debled Marc, Campone Mario, Monnier Alain, Tondini Carlo, McIntosh Christina, Thürlimann Beat, Guerrieri-Gonzaga Aliana, Sun Zhuoxin, Aebi Stefan
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective
Harbeck N, Wuerstlein R, Welt A, Tesch H, Schneeweiss A, Scharl A, von Minckwitz G, Lück H, Huober J, Jackisch C, Hegewisch-Becker S, Decker T, Untch M, Marschner N, Thomssen C. Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective. Breast Care (Basel) 2014; 9:52-9.
Feb 1, 2014Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective
Feb 1, 2014Breast Care (Basel) 2014; 9:52-9
Harbeck Nadia, Wuerstlein Rachel, Welt Anja, Tesch Hans, Schneeweiss Andreas, Scharl Anton, von Minckwitz Gunter, Lück Hans-Joachim, Huober Jens, Jackisch Christian, Hegewisch-Becker Susanna, Decker Thomas, Untch Michael, Marschner Norbert, Thomssen Christoph
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Aebi S, Mamounas E, Geyer C, Price K, Coates A, Gelber R, Rastogi P, Wolmark N, Wapnir I, Murray E, Thürlimann B, Cañada J, Gelber S, Anderson S, Láng I, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 2014; 15:156-63.
Jan 16, 2014Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Jan 16, 2014Lancet Oncol 2014; 15:156-63
Aebi Stefan, Mamounas Eleftherios P, Geyer Charles E, Price Karen N, Coates Alan S, Gelber Richard D, Rastogi Priya, Wolmark Norman, Wapnir Irene L, Murray Elizabeth, Thürlimann Beat, Cañada José Manuel Baena, Gelber Shari, Anderson Stewart J, Láng István, Robidoux Andre, Martín Miguel, Nortier Johan W R, Paterson Alexander H G, Rimawi Mothaffar F, CALOR investigators
[Combined modality treatment of oesophageal cancer]
Stahl M, Ruhstaller T. [Combined modality treatment of oesophageal cancer]. Internist (Berl) 2014; 55:7-14.
Jan 1, 2014[Combined modality treatment of oesophageal cancer]
Jan 1, 2014Internist (Berl) 2014; 55:7-14
Stahl M, Ruhstaller Thomas
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
Gnant M, Steger G, Balic M, Ressler S, Cowens J, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T, Bartsch R, Fitzal F, Dubsky P, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2013; 25:339-45.
Dec 16, 2013Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
Dec 16, 2013Ann Oncol 2013; 25:339-45
Gnant M, Steger G, Balic M, Ressler S, Cowens J W, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T O, Bartsch R, Fitzal F, Dubsky P, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer Michael, Singer C, Jakesz R, Austrian Breast and Colorectal Cancer Study Group
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Huober J, Thürlimann B, Gelber R, Colleoni M, Coates A, Goldhirsch A, Price K, Wardley A, Smith I, Láng I, Neven P, Forbes J, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 2013; 143:159-69.
Dec 5, 2013Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Dec 5, 2013Breast Cancer Res Treat 2013; 143:159-69
Huober J, Thürlimann Beat, Gelber R D, Colleoni M, Coates A S, Goldhirsch A, Price K N, Wardley A, Smith I, Láng I, Neven P, Forbes J F, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B F, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
von Minckwitz G, Costa S, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Blohmer J, Hanusch C, Rezai M, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Untch M. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Ann Oncol 2013; 25:81-9.
Nov 21, 2013Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
Nov 21, 2013Ann Oncol 2013; 25:81-9
von Minckwitz G, Costa S D, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Blohmer J U, Hanusch C, Rezai M, Fasching P A, Huober Jens, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Untch M
Late term tolerance in head neck cancer patients irradiated in the IMRT era.
Studer G, Linsenmeier C, Riesterer O, Najafi Y, Brown M, Yousefi B, Bredell M, Huber G, Schmid S, Studer S, Zwahlen R, Rordorf T, Glanzmann C. Late term tolerance in head neck cancer patients irradiated in the IMRT era. Radiat Oncol 2013; 8:259.
Nov 5, 2013Late term tolerance in head neck cancer patients irradiated in the IMRT era.
Nov 5, 2013Radiat Oncol 2013; 8:259
Studer Gabriela, Linsenmeier Claudia, Riesterer Oliver, Najafi Yousef, Brown Michelle L, Yousefi Bita, Bredell Marius, Huber Gerhard, Schmid Stephan, Studer Stephan, Zwahlen Roger A, Rordorf Tamara, Glanzmann Christoph
Regulation of Endothelial Permeability in the Corpus Luteum: A Review of the Literature
Herr D, Bekes I, Wulff C. Regulation of Endothelial Permeability in the Corpus Luteum: A Review of the Literature. Geburtshilfe Frauenheilkd 2013; 73:1107-1111.
Nov 1, 2013Regulation of Endothelial Permeability in the Corpus Luteum: A Review of the Literature
Nov 1, 2013Geburtshilfe Frauenheilkd 2013; 73:1107-1111
Herr D, Bekes Inga, Wulff C
Local Renin-Angiotensin system in the reproductive system
Herr D, Bekes I, Wulff C. Local Renin-Angiotensin system in the reproductive system. Front Endocrinol (Lausanne) 2013; 4:150.
Oct 18, 2013Local Renin-Angiotensin system in the reproductive system
Oct 18, 2013Front Endocrinol (Lausanne) 2013; 4:150
Herr Daniel, Bekes Inga, Wulff Christine
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
Gerber B, Jackisch C, Kunz G, Blohmer J, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013; 24:2978-84.
Oct 17, 2013Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
Oct 17, 2013Ann Oncol 2013; 24:2978-84
Gerber B, Jackisch C, Kunz G, Blohmer J U, Huober Jens, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P A, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial
Banys M, Wallwiener D, Hirnle P, Wackwitz B, Kraemer B, Huober J, Becker S, Lueck H, Krawczyk N, Janni W, Gebauer G, Solomayer E, Fehm T. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC cancer 2013; 13:480.
Oct 15, 2013Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial
Oct 15, 2013BMC cancer 2013; 13:480
Banys Malgorzata, Wallwiener Diethelm, Hirnle Peter, Wackwitz Birgit, Kraemer Bernhard, Huober Jens, Becker Sven, Lueck Hans-Joachim, Krawczyk Natalia, Janni Wolfgang, Gebauer Gerhard, Solomayer Erich-Franz, Fehm Tanja